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WRPOSE: To assess the feasibility of somatostatin 
receptor scintigraphy for patients with Cushing’s 
syndrome caused by tumors secreting ectopic 
corticotropin or cotticotropin-releasing hormone 
(CRH). 
PATIENTS AND METHODS: Ten patients with Cushing’s 
syndrome, nine with ectopic corticotropin- 
secreting tumors and one with a CRH-secreting 
tumor, were consecutively studied. For 
comparison purposes, eight patients with 
corticotropin-secreting pituitary tumors and one 
patient with an autonomous adrenal adenoma 
were investigated. In vivo tumor localization was 
performed for all patients using a radionuclide- 
coupled somatostatin analog. The results obtained 
with this technique were compared with those 
obtained with conventional imaging techniques. 
For some patients, the clinical effects of 
octreotide therapy were evaluated. 
RESULTS: Somatostatin analog scintigraphy 
successfully identified the primary ectopic 
corticotropin-secreting and CRH-secreting 
tumors or their metastases, or both, in 8 of 10 
patients; in 2 patients with cotticotropin-secreting 
bronchial carcinoids, the tumors could not be 
visualized. Normal scans were obtained for the 8 
patients with cotticotropin-secreting pituitary 
tumors and the one patient with an adrenal 
adenoma. 
CONCLUSION: Somatostatin analog scintigraphy can 
be included as a diagnostic step in the workup of 
Cushing’s syndrome patients with a suspected 
ectopic corticotropin-secreting tumor or a CRH- 
secreting tumor. 
From the Department of Internal Medicine III (WWDH, HAPP, LJH, SWJL), 
Department of Nuclear Medicine (EPK, DJK, HYO), Department of 
Surgery (HAB), University Hospital Dijkzigt, Rotterdam, the Netherlands; 
Department of Suraerv (CDM), Surgical Research Center, Universitv of 
Connecticut Health-Center, Farmington, Conn.; Division of Cell Biology 
and Experimetnal Cancer Research (JCR), lnstitutue of Pathology, 
University of Bern, Bern, Switzerland; Department of Internal Medicine 
(FREN), Onze Lieve Vrouw Hospital, Aalst, Belgium. 
Requests for reprints should be addressed to Wouter W. de Herder, 
MD, Department of Internal Medicine Ill, University Hospital Dijkzigt, Dr. 
Molewaterplein 40, 3015 GD Rotterdam, the Netherlands. 
Manuscript submitted February 15, 1993, and accepted in revised form 
June 17, 1993. 
T umorous secretion of peptides derived from proopiomelanocortin, including biologically ac- 
tive corticotropin, is one of the many humoral syn- 
dromes of cancer. It accounts for about 15% to 20% 
of cases of Cushing’s syndrome from all causes.lJ 
Medullary thyroid carcinomas, small cell hmg can- 
cers, carcinoids, pancreatic islet cell tumors, 
pheochromocytomas, and paragangliomas account 
for approximately 80% of the cases. For the majority 
of patients with ectopic corticotropin secretion, the 
typical Cushing’s syndrome habitus is absent. The 
clinical picture is typified by the sudden appearance 
and rapid progression of signs of extreme hypercor- 
tisolemia, including hypertension, edema, weakness, 
hypokalemia, and glucose intolerance; plasma corti- 
cotropin concentrations are often very high and may 
be associated with hyperpigmentation. These signs 
may be accompanied by manifestations of the malig- 
nancy causing the hypercortisolism. In patients with 
occult tumors, however, differentiating between an 
ectopic and a pituitary source of corticotropin may 
be difficult.84 
Long-term therapy with the somatostatin analog 
octreotide for patients with carcinoids, pancreatic 
islet cell tumors, and medullary thyroid carcinomas 
has been reported to control hormonal hypersecre- 
tion, improve symptomatology, and in some cases, 
reduce tumor growth. Corticotropin secretion of pi- 
tuitary-dependent Cushing’s syndrome (Cushing’s 
disease) usually does not respond to octreotide, but 
the agent has been successfully used to control ec- 
topic corticotropin secretion caused by neuroen- 
docrine tumors.5-7 Visualization of somatostatin-re- 
ceptor-positive tumors in vivo after intravenous 
injection of [lz31-TyS]-octreotide or [l”In-DTPA-D- 
Phe’]-octreotide has been successful with a number 
of human tumors.81o 
We report our experience with somatostatin re- 
ceptor scintigraphy for 10 patients with Cushing’s 
syndrome and clinical evidence of ectopic corti- 
cotropin production or tumors secreting corti- 
cotropin-releasing hormone, and for 5 patients with 
Cushing’s disease, 3 patients with Nelson’s syndrome, 
and 1 patient with Cushing’s syndrome caused by an 
adrenal adenoma. The clinical response to octreotide 
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Figure 1. Lateral image of the head and neck of patient 1, 24 
hours after injection of [*llln-DTPA-D-Phell-octreotide. Note the 
asymmetrical accumulation of radioactivity in the thyroid (large 
arrow) and in the lymph node metastases lateral to the right 
thyroid lobe (small arrows), whereas accumulation in the pituitary 
is normal (open arrow). 
therapy was studied in 7 patients with Cushing’s syn- 
drome caused by ectopic corticotropin or CRH se- 
cretion. Tumor samples of 6 patients were examined 
for somatostatin analog-binding sites by in vitro au- 
toradiography with [ 1251-Ty?]-octreotide. 
METHODS 
The somatostatin analogs [Ty8]-octreotide and 
[DTPA-D-Phel]-octreotide (Sandoz, Basel, Switzer- 
land) were labeled with 123 I and 111 In, respectively, 
as described elsewhere.11312 The scintigraphic tech- 
nique used with these compounds to visualize so- 
matostatin-receptor-positive tumors has been de- 
scribed previously.810~13~14 In vivo receptor imaging 
with [1231-Ty?]-octreotide has drawbacks: The avail- 
ability of chemically pure 1231 is limited, it has a rather 
short half-life, and its predominant hepatobiliary 
clearance makes recognizing abdominal tumors diffi- 
cult. Most of these negative aspects have been over- 
come by replacing [1231-Tyra]-octreotide with [“%r- 
DTPA-D-Phel]-octreotide. lo-i2 In the present study we 
initially used [1231-w]-octreotide with two patients, 
but when [lllIn-DTPA-D-Phel]-octreotide became 
available to us, we used it with all other patients. 
Somatostatin analog-binding sites were also deter- 
mined in vitro by autoradiography on cryostat sec- 
tions of the tumor tissues of five patients, as de- 
scribed before.13 
Serum and urinary cortisol were measured by ra- 
dioimmunoassay (Diagnostic Products Corporation, 
Los Angeles, California). Since tumors producing cor- 
Figure 2. Anterior image of the chest of patient 4, 24 hours after 
injection of [lllln-DTPA-D-Phell-octreotide. Note the accumulation of 
radioactivity in the mediastinal lymph node metastases (arrows), 
whereas uptake in the liver, kidneys, and spleen is normal. 
ticotropin ectopically may also produce “big” corti- 
cotropin or biologically active fragments of corti- 
cotropin, or both, We preferred to measure plasma 
corticotropin (ACTH,,,) by radioimmunoassay (Med- 
genix, F’leurus, Belgium) rather than by the more spe- 
cific two-site immunoradiometric assay. Cortico- 
tropin-releasing hormone,, was measured by 
immunoradiometric assay (Dr EA. Linton, Depart- 
ment of Biochemistry and Physiology, University of 
Reading School of Animal and Microbial Sciences, 
Reading, UK). 
In all cases, the diagnosis was confirmed by histo- 
logic examination of stained tissue sections. 
Preparations from seven patients were also studied 
by immunohistochemistry using an anticorticotropin 
antiserum. Tumor cells of two patients were cultured 
according to previously described methods.14 
All patients gave informed consent to participate in 
this study, which was approved by the ethics com- 
mittee of our hospital. 
RESULTS 
Clinical, Biochemical, and 
Pathologic Features 
The diagnosis of Cushing’s syndrome was sus- 
pected for all 10 patients by their clinical presenta- 
tion and was subsequently confiied by endocrino- 
logic testing. Serum cortisol levels were elevated in 
all patients and were suppressed insufticiently in re- 
sponse to 1 mg dexamethasone in nine of the patients 
studied. Urinary cortisol excretion and serum corti- 
cotropin levels were also increased in all patients 
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TABLE I 
Endocrinologic Parameters for 10 Patients with Cushing’s Syndrome Caused by Ectopic 
Corticotropin or Corticotropin-Releasing Hormone Secretion 
Patient Cottisol (0800 hours) Urinary Cortisol Excretion Dexamethasone Screening Test* Corticotropin 
Number nmol/L nmol/24h nmol/L pmol/L 
1 2,300 20,000 NA 20 
2 655 1,800 498 20 
3 4,865 14,000 3,834 70 
4 1,860 30,000 1,320 >400 
5 3,267 33,000 1,400 84 
6 550 1,500 411 26 
7 1,180 12,000 883 39 
8 608 4,400 579 44 
9 882 2,600 773 10 798 5 3 540 :; 
Normal <430 <510 <140 <ll 
*Serum cortisol at 8:00 AM. after oral administration of 1 mE! dexamethasone at 11:OO PM the previous evening 
NA = not available. 
(Table I). Six patients had hypokalemia, which was 
not related to the use of diuretics. Five patients had 
hypertension (systolic blood pressure greater than 
160 mm Hg or diastolic blood pressure greater than 
90 mm Hg). Four patients had glucose intolerance (as 
defined by random venous plasma glucose levels of 
11.1 mmol/L or higher). 
Metastatic (sporadic) medullary thyroid carcinoma 
was diagnosed in patients 1, 2, and 3 (Table II). 
Tumor biopsies from these three patients did not stain 
positively for corticotropin. In patient 1, however, cul- 
tured tumor cells prepared from a cervical lymph 
node metastasis showed 380 pg CRH/106 cells but no 
corticotropin. Corticotropin and CRH levels in the 
conditioned medium from the cultured tumor cells 
were below the detection limit of the assay used. 
These results suggest this tumor was ectopically pro- 
ducing CRH rather than corticotropin. 
positive staining for corticotropin, but cultured tumor 
cells produced small amounts of corticotropin. 
Scintigraphic and Radiographic Evaluation 
A bone marrow smear from patient 4 showed a dif- 
fusely infiltrating anaplastic small cell carcinoma, and 
based on additional clinical and radiologic data, small 
cell lung cancer was diagnosed. In patients 5 and 10, 
solitary bronchial carcinoids 1.5 cm and 1.8 cm in di- 
ameter, respectively, were removed at thoracotomy. 
In both cases, no lymph node enlargement was de- 
tected. In patient 6, a corticotropin-producing bron- 
chial carcinoid was removed 3-l/2 years before 
Cushing’s syndrome clinically recurred; a bronchial 
carcinoid recurrence was suspected, but no tumor lo- 
calizations were detected. In patient 7, resection of a 
bronchial carcinoid and two paraesophageal lymph 
node metastases resulted in transient remission of 
Cushing’s syndrome. A metastatic thymic carcinoid 
was found in patient 8, and a metastatic pancreatic 
gastrinoma was diagnosed in patient 9. Tumor tissue 
from patients 5, 7, 9, and 10 contained immunoreac- 
tive corticotropin, strongly suggesting that the tumors 
were the source of the hormone. Immunohisto- 
chemistry of tumor tissue from patient 8 did not show 
Octreotide scintigraphy demonstrated uptake of 
the radionuclide-coupled somatostatin analog in sev- 
eral tumor localizations-also identified by abdomen 
and thorax computerized tomography (CT), neck and 
abdomen ultrasonography, and bone scintigraphy 
(Table II)-for patients 1, 2, and 3 with metastatic 
medullary thyroid carcinoma Tumor localizations in 
the liver of all three patients and in a retroperitoneal 
lymph node in patient 1 were not detected by oc- 
treotide scintigraphy (Figure 1, Table II). Octreotide 
scintigraphy did show abnormal uptake in the medi- 
astimm, the bony pelvis, the lumbar spine, and the 
proximal femoral bone of patient 4 with small cell 
hmg cancer (Figure 2). Routine chest roentgenogra- 
phy of this patient did not show abnormalities; bone 
scintigraphy was normah and a CT scan of the chest 
identified mediastinal lymphadenopathy but the pri- 
mary lung tumor was not seen. 
Patient 5 had a solitary bronchial carcinoid, shown 
on chest roentgenogram and CT scan as a single in- 
trapulmonary mass in the right middle lobe. 
Octreotide scintigraphy did not show pathologic up- 
take of the radiopharmaceutical. In patient 6, who had 
Cushing’s syndrome recurrence after removal of a 
corticotropin-producing bronchial carcinoid, no 
metastatic carcinoid lesion could be identified by CT 
scanning or by magnetic resonance (MR) imaging of 
the chest. Octreotide scintigraphy was negative for 
this patient, and the localization of tumor tissue is still 
LlllhOWll. 
Patient 7 had a metastatic bronchial carcinoid, and 
octreotide scintigraphy demonstrated uptake in the 
left lower lobe of the lung and in the mediastinum 
(Figure 3A). A contrast-enhanced CT scan of the tho- 
rax with attention to the left lower lobe identified a 
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TABLE II 
Features of 10 Patients with Ectopic Cotticotropin or Corticotropin-Releasing Hormone Secretion 
Patient Age Tumor Octreotide In vitro In vivo Response 
Number (Y) Sex Diagnosis Localizations* Scintigraphy Autoradiography to Octreotide 
1 38 M M-K Thyroid + NA Plasma corticotropin 
Neck + + decreased by 41% 
Liver 
Retroperitoneal node - 
2 45 F MTC Bone + NA NA 
Neck + 
Supraclavicular (L) + NA 
Lungs + NA 
Mediastinum + NA 
Liver NA 
3 35 M MTC Neck + NA Plasma corticotropin 
Lungs + NA decreased by 60% 
Mediastinum + NA 
Liver NA 
4 61 F SCLC Mediastinum + NA Urinary cortisol 
Bone marrow + NA excretion decreased 
by 54% 
5 65 M Carcinoid Right middle lobe lung - NA NA 
6 36 F Carcinoid Unknown localization - NA No response 
7 26 F Carcinoid Left lower lobe lung + + Plasma corticotropin 
Paraesophageal nodes + + decreased by 30% 
8 35 F Carcinoid Thymus f Plasma corticotropin 
Mediastinal nodes + I& decreased by 88% 
9 37 M Gastrinoma Pancreas (2 tumors) f + Plasma corticotropin 
Lymph node + + and urinary cortisol 
excretion normalized 
10 42 M Carcinoid Left lower lobe lung + + NA 
* Known by physical examination, radiologic techniques, surgery, or autopsy. 
NA = not available; MTC = medullary thyroid carcinomas; SCLC = small cell lung cancer. 
10 x 15 mm lesion in the left lower lobe of the lung 
but no mediastinal lymphadenopathy (Figure 3B). 
Review of the CT scan performed 6 months earlier 
revealed a 5 x 8 mm lesion at the same location that 
could not be distinguished from blood vessels cut at 
an oblique angle, since they were of similar size. 
In patient 8, a CT scan of the chest showed a non- 
homogeneous tumor mass within the anterior medi- 
astinum and enlarged paratracheal lymph nodes. A 
CT scan of the abdomen was normal, but octreotide 
scintigraphy demonstrated uptake in a large medi- 
astinal mass (Figure 4). In patient 9, octreotide 
scintigraphy indicated three tumors in the region of 
the pancreas; no abnormalities in liver uptake were 
seen. Computerized tomography revealed a tumor in 
the corpus of the pancreas as well as an enlarged 
lymph node in the liver hihrs, but no detectable liver 
metastases.14 Patient 10 had a solitary bronchial car- 
cinoid. A chest roentgenogram was normal, but oc- 
treotide scintigraphy showed uptake in the left lower 
lobe of the lung; a contrast-enhanced CT scan of the 
thorax with attention to the left lower lobe revealed 
a solitary 12 x 18 mm lesion there. 
Autoradiography 
In vitro somatostatin receptor autoradiography 
was performed on tumor samples from patients 1,2, 
7,8,9, and 10. In vitro, a cervical lymph node metas- 
tasis sample from patient 1, who had metastatic 
medullary thyroid carcinoma, contained somatostatin 
analog-binding sites, whereas abdominal lymph node 
metastasis and liver metastasis samples from the 
same patient were negative (Figure 5). A cervical 
lymph node metastasis sample from patient 2 was 
also negative. High mrmbers of somatostatin analog- 
binding sites were present in tumor samples from the 
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Figure 4. Anterior chest image of patient 8, 24 hours after 
injection of [lllln-DTPA-D-Phell-octreotide. Note the accumulation of 
radioactivity in the large mediastinal carcinoid tumor. 
Scintigraphic Evaluation of Control Patients 
Normal scans were obtained for eight patients with 
corticotropin-secreting pituitary tumors (five had 
Cushing’s disease and three had Nelson’s syndrome), 
and for one patient with Cushing’s syndrome caused 
by a cortisol-secreting adrenal adenoma. 
COMMENTS 
Figure 3. Posterior image of the chest of patient 7, 24 hours 
after injection of [lllln-DTPA-D-Phell-octreotide (A). Note the 
accumulation of radioactivity in the left lower lobe of the lung 
(large arrow) and the mediastinum (small arrows). Computed 
tomography scan of the chest of the same patient(B) shows a 15 
x 10 mm lesion in the left lower lobe of the lung (arrow). 
metastatic bronchial carcinoid of patients 7 and 10 
and from the thymic carcinoid of patient 8, and also 
in specimens of the primary pancreatic gastrinomas 
and a lymph node metastasis of patient 9 (Table II). 
Clinical Results of Octreotide Treatment 
The clinical responses to octreotide (0.15 to 1.5 
mg/day) were monitored in seven patients (Table II). 
Reductions of 25% to 100% in serum corticotropin or 
in urinary cortisol excretion, or both, could be 
demonstrated for all patients, except patient 6. 
Recurrence of a corticotropin-producing bronchial 
carcinoid was suspected for patient 6 but not identi- 
fied, and no significant suppression -of the urinary se- 
cretion of cortisol was found even with high doses of 
octreotide (1.5 mg/day intravenously). 
Patients with the ectopic corticotropin secretion 
syndrome usually have obvious underlying tumors, 
most commonly neuroendocrine tumo~&~; however, 
as many as 30% of corticotropin-producing neuroen- 
docrine tumors go undetected for a long time.3l4 
Because these occult neuroendocrine tumors may be 
potential malignancies, determined attempts at early 
localization must be made before metastases or local 
invasions prevent curative treatment4 When evaluat- 
ing patients with suspected ectopic corticotropin se- 
cretion, CT and MR imaging of the chest and abdomen 
are the best localization methods currently avail- 
able.3,4J5 Even so, identifying a mass does not prove 
its function, and some tumors remain occult. Hence, 
a study that reveals both structure and function is 
needed, but the approaches tried thus far have met 
with limited success. Extensive selective venous 
catheterization and blood sampling is only occasion- 
ally successful in localizing an ectopic source2-‘$ and 
bilateral simultaneous petrosal sinus blood sampling 
helps exclude a pituitary source of Cushing’s syn- 
drome but does not localize the true source of corti- 
cotropin.15 The results of our study suggest that so- 
matostatin receptor scintigraphy is useful for 
identifiying ectopic sources of corticotropin and CRH. 
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Abnormalities in the control of glucocorticoid se- 
cretion and elevated levels of corticotropin have been 
observed in as many as 30% of cases of small cell lung 
cancer, but they lead to clinically recognized Cushing’s 
syndrome in fewer than 5%.16J7 Tumorous cortico- 
tropin production may occasionally dominate the 
clinical picture of patients with bronchial and thymic 
carcinoids. 1s-20 As many as 30% of gastrinomas contain 
corticotropin-like immunoreactivity, but the full-blown 
clinical picture of Cushing’s syndrome occurs in ap- 
proximately 3% of patients with these gastrinomas.21 
A few cases of ectopic production of CRH, with or 
without corticotropin, by medullary thyroid carcino- 
mas and carcinoids have been reported in the litera- 
ture.22,23 Corticotropin-releasing hormone stimulates 
corticotropin production from anterior pituitary cells, 
causing characteristics of Cushing’s disease rather 
than the classical ectopic corticotropin syndrome. In 
these cases, catheterizing the petrosal sinus may 
falsely point to a diagnosis of Cushing’s disease. 
Ectopic CRH secretion rather than corticotropin se- 
cretion by a metastatic medullary thyroid carcinoma 
was documented as the cause of Cushing’s syndrome 
in patient 1. Bilateral simultaneous petrosal sinus 
blood sampling for corticotropin was not done for this 
patient, however, and pituitary MR imaging did not 
show abnormalities. 
In vitro labeling of somatostatin analog-binding 
sites, as demonstrated by autoradiography using [ 1251- 
Tyr?]-octreotide, has been reported successful in 6 of 
26 medullary thyroid carcinoma tumor samples,24 in 
4 of 7 small cell lung cancer samples and in none of 
17 non-small cell lung cancer samples,25J6 in 54 of 62 
samples from different carcinoid tumor localiza- 
tions,27 and in 10 of 14 endocrine pancreatic tumor 
specimens.28 
The radiopharmaceuticals [1231-Ty13]-octreotide and 
[i”In-DTPA-D-Phelloctreotide are suitable com- 
pounds for in vivo localizing of somatostatin-receptor- 
positive tum~rs.‘~~~ For visualizing these tumors, 
[lllIn-DTPA-D-Phel]-octreotide seems superior to [1231- 
Tyrj]-octreotide, especially when they are located in 
the upper part of the abdomen. A positive localization 
by in vivo somatostatin receptor scintigraphy corre- 
lates well with the presence of somatostatin analog- 
binding sites in vitr~.~~~,~~ To date, visualizing the pri- 
mary medullary thyroid carcinoma and its metastases 
with radiolabeled octreotide has been successful in 11 
of 17 patients in our ~linic.~~ Small cell lung cancers 
and their metastases were visualized in 5 of 8 pa- 
tients,2g and primary carcinoids and their metastases 
were visualized in 32 of 37 patientsi Metastatic gas- 
trinomas have been demonstrated in all 12 patients 
studied by us so far.lO In our series of patients with 
ectopic corticotropin production, the primary tumor 
as well as most secondary tumor deposits were suc- 
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Figure 5. In vitro autoradiography of the lymph node metastases 
from the neck (A-C) and abdomen (D-F) from patient 1. 
Hematoxylin-eosin stained sections (A, D). Autoradiograms 
showing total binding of P5CTyr31-octreotide (B, E); note the 
labeling (black areas) in the lymph node metastasis from the neck 
(BC,F), which is absent in the abdominal lymph node metastasis 
(E). Nonspecific binding with 1 mmol/L [Tyr31-octreotide (C, F). 
Bar = 1 mm. 
cessfully visualized in 8 of the 10 patients (Table ID. 
Successful control of ectopic corticotropin release 
by octreotide has been reported in patients with 
metastatic medullary thyroid carcinomas,3o lung car- 
cinoids,31z32 and gastrinomas,33,34 although therapy 
failures have also been reported.35B6 In our series, a 
decrease-and in one case normalization-of plasma 
corticotropin concentration or urinary cortisol se- 
cretion, or both, in response to octreotide treatment 
was observed for six patients with somatostatin-re- 
ceptor-positive tumors; no effects of octreotide ther- 
apy were observed for one patient with an occult cor- 
ticotropin-producing tumor and negative octreotide 
scintigraphy. Thus, the receptor status of the tumor 
seems predictive for the corticolropin- and cortisol- 
lowering effects of octreotide. 
Somatostatin receptor scintigraphy demonstrated 
uptake in the primary tumor and in the cervical lymph 
node metastases of a patient with me&static 
medullary thyroid carcinoma, but not in the distant 
liver metastases nor in a retroperitoneal lymph node 
metastasis. Similarly, in vitro receptor autoradiogra- 
phy for somatostatin analog-binding sites was posi- 
tive for the cervical lymph node metastasis sample, 
but negative for the liver metastasis sample. That sug- 
gests that the receptor-negative tumor localizations 
showed another degree of differentiation. Moreover, 
liver tumor localizations could not be detected in two 
other patients with me&static medullary thyroid car- 
cinoma; and in vivo somatostatin receptor imaging 
recognized the liver metastases in only 7 of 17 pa- 
tients with medullary thyroid carcinoma and docu- 
mented liver metastases.10~24~37 Presumably the normal 
accumulation of radioactivity in the liver prevents the 
detection of small metastases, which bind somato- 
310 April 1994 The American Journal of Medicine Volume 96 
SCINTIGRAPHY FOR LOCALIZING TUMORS IN CUSHING’S SYNDROME/ DE HERDER ET AL 
statin to an extent similar to normal liver cell uptake 
of the radionuclide-coupled somatostatin analog. 
That means that somatostatm receptor scintigraphy 
should be combined with an ultrasound examination 
of the liver for patients with metastatic neuroen- 
docrine tumors. 
1246-1249. 
Our findings in the control group are in accordance 
with previous observations suggesting that corti- 
cotropin-secreting pituitary tumors and cortisol-pro- 
ducing adrenal adenomas are somatostatm receptor 
negative. 7Jo 
10. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its 
analogs in the treatment of tumors. Endocr Rev. 1991;12:450-482. 
11. Bakker WH, Krenning EP, Breeman WA, et al. Receptor scintigraphy with a 
radioiodinated somatostatin analogue: radiolabeling, purification, biological 
activity, and in viva application in animals. J Nucl Med. 1990;71:1501-1509. 
12. Bakker WH, Albert R, Bruns C, et al. [‘%DTPA-D-Phelloctreotide, a 
potential radiopharmaceutical for imaging of somatostatin receptor-positive 
tumors: synthesis, radiolabeling and in vitro validation. Life Sci. 
1991;49:1583-1591. 
Only four patients had potential occult ectopic cor- 
ticotropin-secreting tumors (patients 4, 6, 7, and 10). 
Somatostatin receptor scintigraphy visualized the pri- 
mary tumors as well as their metastases in three of 
these patients, but the tumor localization in one pa- 
tient remains unknown. While these results are en- 
couraging and suggest that somatostatin receptor 
scintigraphy may be useful for finding those clinically 
frustrating occult sources of corticotropin, more pa- 
tients will need to be studied to determine the tech- 
nique’s true usefulness. 
13. Krenning EP, Bakker WH, Kooij PPM, et al. Somatostatin receptor 
scintigraphy with [In-lllDTPA-D-Phe*l-octreotide in man: metabolism, dosimetry 
and comparison with [1231-Tyr31-octreotide. J Nucl Med. 1992;33:652-658. 
14. Lamberts SWJ, Hofland LJ, van Koetsveld PM, et al. Parallel in viva and in 
vitro detection of functional somatostatin receptors in human endocrine 
pancreatic tumors: consequences with regard to diagnosis, localization, and 
therapy. J Clin Endocrinol Metab. 1990;71:566-574. 
15. Findling JW, Kehoe ME, Shaker JL, Raff H. Routine inferior petrosal sinus 
sampling in the differential diagnosis of adrenocorticotropin (ACTHLdependent 
Cushing’s syndrome: early recognition of the occult ectopic ACTH syndrome. J 
Clin Endocrinol Metab. 1991;73:408-413. 
16. Bondy PK, Gilby ED. Endocrine function in small cell undifferentiated lung 
cancer. Cancer. 1981;50:2147-2153. 
Scintigraphy with radiolabeled octreotide provides 
a new noninvasive technique for the in vivo detection 
of a variety of tumors, and [lllIn-DTPA-D-Phel]-oc- 
treotide scintigraphy can be included as a diagnostic 
step in the workup of patients with Cushing’s syn- 
drome, especially when the diagnosis of ectopic cor- 
ticotropin or CRH secretion is considered. We found 
a positive correlation between octreotide scintigra- 
phy and the clinical response of Cushing’s syndrome 
to octreotide therapy, but it must be realized that the 
drug therapy seldom completely controls adrenocor- 
tical hyperfunction in these patients. 
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